In Greece, the economic crisis is deepening, affecting most severely the one third of the population (over 3.5 million people) that lives below the poverty line. Unemployment is constantly hitting new gloomy records, coming close to 30% and expected soon to rise further to 33-34%, and the problem is expected to increase.
An estimated total of 3,000,000 citizens have insufficient or no health care coverage, the Greek pharmaceutical association, the SFEE points out, noting that it is therefore clear that the economic crisis has evolved into a humanitarian crisis, as almost one third of the population, most notably the uninsured and indigent citizens, have insufficient or no access to healthcare services!
As part of its CSR Program and wishing to make an effective contribution to public health and support those really in need, the SFEE has decided to establish a Bank of Medicines – Network for the Free Distribution for indigent and uninsured citizens. By this initiative, the SFEE aims to integrate the various actions undertaken by individual companies and show tangible proof of its active contribution and commitment to addressing a social need that is growing to enormous proportions. The initiative is under the auspices of the Ministry of Health and the scientific supervision of the National Organization for Medicines (EOF).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze